We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





3D Printing Paves Way for New Type of COVID-19 Lateral Flow Test with More Capabilities

By LabMedica International staff writers
Posted on 11 May 2021
Researchers have developed a 3D printing technique that extends the possibilities of COVID-19 lateral flow tests and enable production of quick, cheap, and easy to use advanced diagnostic tests.

Using a 3D printer, bioengineers at KU Leuven (Leuven, Belgium) have fabricated a 3D version of a lateral flow test. More...
The basis is a small block of porous polymer, in which ‘inks’ with specific properties are printed at precise locations. In this way, a network of channels and small ‘locks’ is printed that let the flow through or block it where and when necessary, without the need for moving parts. During the test, the sample is automatically guided through the different test steps. That way, even complex protocols can be followed.

The researchers evaluated their technique reproducing an ELISA test (Enzyme-Linked Immunosorbent Assay), which is used to detect immunoglobulin E (IgE). Ig E is measured to diagnose allergies. In the lab, this test requires several steps, with different rinses and a change in acidity. The research team was able to run this entire protocol using a printed test kit the size of a thick credit card. The technique not only offers opportunities for cheaper and faster diagnosis in developed countries, but also in countries where the medical infrastructure is less accessible and where there is a strong need for affordable diagnostic tests. The 3D printing technique is also affordable and scalable.

“The great thing about 3D printing is that you can quickly adapt a test’s design to accommodate another protocol, for example, to detect a cancer biomarker. For the 3D printer it does not matter how complex the network of channels is,” said Dr. Cesar Parra. “In our lab, producing the Ig E prototype test costs about USD 1.50, but if we can scale it up, it would be less than USD 1.”

Related Links:
KU Leuven


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: An innovative deep learning model can accurately predict MSI tumor and immune checkpoint inhibitor responsiveness (Photo courtesy of Jae-Ho Cheong/Yonsei University College of Medicine)

AI Model Accurately Predicts MSI Tumor and Immune Checkpoint Inhibitor Responsiveness

One in three people is expected to develop cancer in their lifetime, and a key factor in patient prognosis is the tumor’s microsatellite status—whether it is stable or shows microsatellite instability-high (MSI-H).... Read more

Industry

view channel
Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)

Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has entered into an agreement with Mdxhealth SA (Irvine, CA, USA), which will acquire its Exosome Diagnostics Inc. (Waltham, MA, US) business, including the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.